High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis

References

• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903–911. doi:10.1016/s0140-6736(01)06075-5
   PubMed Web of Science ®Google Scholar
• Lundstrom E, Kallberg H, Alfredsson L, Klareskog L, Padyukov L. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum. 2009;60(6):1597–1603. doi:10.1002/art.24572
   Web of Science ®Google Scholar
• Koziel J, Mydel P, Potempa J. The link between periodontal disease and rheumatoid arthritis: an updated review. Curr Rheumatol Rep. 2014;16(3):408. doi:10.1007/s11926-014-0408-9
   PubMed Web of Science ®Google Scholar
• Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis. 2005;183(2):308–315. doi:10.1016/j.atherosclerosis.2005.03.010
   PubMed Web of Science ®Google Scholar
• Feng J, Chen Q, Yu F, et al. Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies. Medicine. 2016;95(8):e2859. doi:10.1097/MD.0000000000002859
   PubMed Web of Science ®Google Scholar
• Gremese E, Carletto A, Padovan M, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res. 2013;65(1):94–100. doi:10.1002/acr.21768
   PubMed Web of Science ®Google Scholar
• Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011;63(2):359–364. doi:10.1002/art.30136
   PubMed Web of Science ®Google Scholar
• Ottaviani S, Gardette A, Tubach F, et al. Body mass index and response to infliximab in rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(4):478–483.
   PubMed Web of Science ®Google Scholar
• Baker JF, Ostergaard M, George M, et al. Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1–2 years. Ann Rheum Dis. 2014;73(11):1923–1928. doi:10.1136/annrheumdis-2014-205544
   Web of Science ®Google Scholar
• Escalante A, Haas RW, Del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med. 2005;165(14):1624–1629. doi:10.1001/archinte.165.14.1624
   PubMedGoogle Scholar
• Vidal C, Barnetche T, Morel J, Combe B, Daien C. Association of body mass index categories with disease activity and radiographic joint damage in rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2015;42(12):2261–2269. doi:10.3899/jrheum.150224
   Web of Science ®Google Scholar
• Iannone F, Fanizzi R, Notarnicola A, Scioscia C, Anelli MG, Lapadula G. Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients. Joint Bone Spine. 2015;82(3):187–191. doi:10.1016/j.jbspin.2014.12.006
   Web of Science ®Google Scholar
• McCulley CB, Barton JL, Cannon GW, et al. Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):422–428.
   Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi:10.1002/art.27584
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–783. doi:10.1038/nri1937
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy. 1991;3(2):143–158. doi:10.1007/BF02172087
   PubMedGoogle Scholar
• Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol. 2004;13(4):193–222. doi:10.1111/j.0906-6705.2004.00205.x
   PubMed Web of Science ®Google Scholar
• Yamakawa T, Tanaka S, Tamura K, et al. Wistar fatty rat is obese and spontaneously hypertensive. Hypertension. 1995;25(1):146–150. doi:10.1161/01.HYP.25.1.146
   Web of Science ®Google Scholar
• Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990;265(3):1531–1536. doi:10.1016/S0021-9258(19)40049-5
   PubMed Web of Science ®Google Scholar
• Loetscher H, Pan YC, Lahm HW, et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell. 1990;61(2):351–359. doi:10.1016/0092-8674(90)90815-V
   Web of Science ®Google Scholar
• Seckinger P, Isaaz S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem. 1989;264(20):11966–11973. doi:10.1016/S0021-9258(18)80161-2
   PubMed Web of Science ®Google Scholar
• Smith CA, Davis T, Anderson D, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 1990;248(4958):1019–1023. doi:10.1126/science.2160731
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes. 1997;46(3):451–455. doi:10.2337/diab.46.3.451
   Web of Science ®Google Scholar
• Fernandez-Real JM, Gutierrez C, Ricart W, Castineira MJ, Vendrell J, Richart C. Plasma levels of the soluble fraction of tumor necrosis factor receptors 1 and 2 are independent determinants of plasma cholesterol and LDL-cholesterol concentrations in healthy subjects. Atherosclerosis. 1999;146(2):321–327. doi:10.1016/S0021-9150(99)00156-2
   Web of Science ®Google Scholar
• Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T. T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin Endocrinol. 2001;54(3):347–354.
   PubMed Web of Science ®Google Scholar
• Aprahamian TR, Sam F. Adiponectin in cardiovascular inflammation and obesity. Int J Inflam. 2011;2011:376909. doi:10.4061/2011/376909
   PubMedGoogle Scholar